-
Omada Health Analysts Say 'Buy' — While It's Still Below IPO Price
Tuesday, July 1, 2025 - 12:03pm | 326Read More...Canaccord Genuity and Needham analysts initiate coverage of Omada Health Inc (NASDAQ:OMDA) with a Buy rating. Canaccord Genuity analyst Richard Close assigns a price target of $27. Needham analyst Ryan MacDonald assigns a price target of $23. Check out other analyst stock ratings. Canaccord...
-
Analyst: When Americans Sneeze, Teladoc And Athenahealth Profit
Monday, January 8, 2018 - 4:51pm | 630Read More...After the CDC released its flu report for the week ending Dec. 30, Canaccord Genuity looked at which companies could benefit from the strong start to the flu season. The report showed that 5.75 percent of U.S. outpatient visits during the week were due to influenza-like illnesses. While not a...
-
Envision Q4 Outlook Disappoints, But All Hope Is Not Lost
Wednesday, November 1, 2017 - 12:01pm | 350Read More...Investors tend to lose confidence in a company's outlook after a stock plunges 30 percent in one day, but that shouldn't be the case when it comes to Envision Healthcare Corporation (NYSE: EVHC), at least according to analysts at Canaccord Genuity. The firm's Richard Close maintains a Buy rating on...
-
Analyst: Buy CRH Medical After An 'Overdone' Selloff
Monday, July 17, 2017 - 11:40am | 361Read More...CRH Medical Corp (NYSE: CRHM)'s 27 percent plunge on Friday in reaction to rate changes by the Medicare & Medicaid Services (CMS) is overdone and investors should consider buying shares on the weakness, Cannacord Genuity's Richard Close said in a report. The proposed changes by the CMS...
-
Canaccord Explains Why Envision-Amsurg Deal Lacked Cash Component
Friday, June 17, 2016 - 1:31pm | 366Read More...The merger between Envision Healthcare Holdings Inc (NYSE: EVHC) and Amsurg Corp (NASDAQ: AMSG) was structured as an all-stock deal under which 0.334 AmSurg share was offered for each share of Envision. Canaccord Genuity explained why the deal didn't contain a cash compent, "While we...
-
Some Analysts Initially Positive On Envision-AmSurg Merger
Thursday, June 16, 2016 - 11:01am | 240Read More...Envision Healthcare Holdings Inc (NYSE: EVHC) and Amsurg Corp (NASDAQ: AMSG) have agreed to merge, which would create an $8.5B revenue entity. Canaccord Genuity’s Richard Close maintained a Buy rating for Envision, with a price target of $32, saying that the initial views on the merger were...
-
Jefferies Still Thinks McKesson is Cheap After Mixed Earnings
Monday, August 2, 2010 - 9:35am | 77Read More...Jefferies analysts Richard Close, Dana Hambly, and Sean Dodge reiterated a Buy rating for McKesson (NYSE: MCK) after mixed earnings numbers. The analysts said, "MCK maneuvered through a challenging quarter and maintained annual guidance despite weak utilization and some Canadian regulatory...
-
Jefferies Initiates Stericycle, Inc With Buy (SRCL)
Friday, July 9, 2010 - 10:40am | 136Read More...Jefferies analysts Richard Close, Sean Dodge, and Dana Hambly initiated coverage of Stericycle, Inc. (NASDAQ: SRCL) with a Buy rating. Stericycle provides regulated waste management services to institutions such as hospitals, pharmaceutical companies, and other generators of regulated waste. The...
-
Jefferies Likes Merger Of Allscripts-Misys Healthcare Solutions (MDRX) And Eclipsys (ECLP)
Thursday, June 10, 2010 - 9:12am | 209Read More...Jefferies & Company analysts Richard Close, Dana Hambly and Sean Dodge said that if the merger of Allscripts-Misys Healthcare Solutions Inc (Nasdaq: MDRX) and Eclipsys Corporation (Nasdaq: ECLP) goes through, the deal will alter the competitive balance in the HCIT segment. The analysts said...
